0.562
전일 마감가:
$0.6102
열려 있는:
$0.6
하루 거래량:
169.69K
Relative Volume:
1.52
시가총액:
$5.31M
수익:
$34.07M
순이익/손실:
$-20.13M
주가수익비율:
-0.0435
EPS:
-12.92
순현금흐름:
$-24.90M
1주 성능:
-12.16%
1개월 성능:
-23.00%
6개월 성능:
-37.56%
1년 성능:
-44.36%
Biofrontera Inc Stock (BFRI) Company Profile
명칭
Biofrontera Inc
전화
781-245-1325
주소
120 PRESIDENTIAL WAY,, WOBURN
BFRI을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
BFRI
Biofrontera Inc
|
0.562 | 6.04M | 34.07M | -20.13M | -24.90M | -12.92 |
![]()
HLN
Haleon Plc Adr
|
11.35 | 50.14B | 14.35B | 1.85B | 0 | 0.4023 |
![]()
ZTS
Zoetis Inc
|
168.63 | 72.38B | 9.29B | 2.52B | 2.28B | 5.57 |
![]()
RDHL
Redhill Biopharma Ltd Adr
|
1.79 | 4.22M | 35.75M | 11.57M | -26.25M | -3.8069 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
15.03 | 45.51B | 30.08B | 710.16M | 4.45B | 0.2182 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.78 | 19.45B | 16.54B | -1.64B | 749.00M | -1.45 |
Biofrontera Inc 주식(BFRI)의 최신 뉴스
Biofrontera stock hits 52-week low at $0.58 amid market challenges - Investing.com India
Biofrontera AG Faces Financial Uncertainty Amid Biofrontera Inc. Payment Issues - TipRanks
Biofrontera Receives Nasdaq Non-Compliance Notice - TipRanks
Roth Capital Decreases Earnings Estimates for Biofrontera - Defense World
Q2 Earnings Forecast for Biofrontera Issued By Roth Capital - Defense World
Biofrontera Inc. (NASDAQ:BFRI) Q1 2025 Earnings Call Transcript - Insider Monkey
Biofrontera (NASDAQ:BFRI) Price Target Lowered to $2.75 at Benchmark - Defense World
Biofrontera, Inc. Earnings Call: Growth Amid Challenges - TipRanks
Benchmark cuts Biofrontera stock target to $2.75, keeps Buy rating By Investing.com - Investing.com Nigeria
Photodynamic Therapy Market Trends Report 2025-2033, Competitive Analysis of Gladerma, Sun Pharma, Biofrontera, Lumibird, Bausch Health, Soligenix, Modulight, and Theralase TechnologiesResearchAndMarkets.com - FinancialContent
Biofrontera (BFRI) Sees Price Target Reduction by Benchmark | BF - GuruFocus
Benchmark cuts Biofrontera stock target to $2.75, keeps Buy rating - Investing.com Australia
Biofrontera (BFRI) Target Price Trimmed After Lower Revenue Perf - GuruFocus
Biofrontera Inc. price target lowered to $2.75 from $7 at Benchmark - TipRanks
Biofrontera signals 2025 record revenue ambitions with new Ameluz patent and cost controls - MSN
Biofrontera Inc. (BFRI) Reports 9% Revenue Growth in Q1 2025 - GuruFocus
Earnings call transcript: Biofrontera Q1 2025 sees revenue rise, stock dips - Investing.com Nigeria
Earnings call transcript: Biofrontera Q1 2025 sees revenue rise, stock dips By Investing.com - Investing.com South Africa
Transcript : Biofrontera Inc., Q1 2025 Earnings Call, May 16, 2025 - marketscreener.com
BFRI Increases Q1 Revenue and Expands Market Presence | BFRI Sto - GuruFocus
Biofrontera extends Ameluz patent to 2043 for acne treatment By Investing.com - Investing.com Nigeria
Biofrontera Inc. reports Q1 EPS (47c) vs. ($2.88) last year - TipRanks
Biofrontera Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Biofrontera Inc. (BFRI) Sees Encouraging Revenue Growth in Q1 | - GuruFocus
Biofrontera Inc. (BFRI) Sees Encouraging Revenue Growth in Q1 | BFRI Stock News - GuruFocus
Biofrontera Inc. Reports First Quarter 2025 Financial Results and Provides a Business Update - The Manila Times
Biofrontera Inc. reports Q1 EPS (47c) vs. (71c) last year - TipRanks
Biofrontera (BFRI) Achieves Patent Approval and Advances Clinica - GuruFocus
Biofrontera Announces New Patent Protection On Ameluz Until 2043 - marketscreener.com
Biofrontera (BFRI) Achieves Patent Approval and Advances Clinical Trials | BFRI Stock News - GuruFocus
Biofrontera's Revised Ameluz Formulation Receives US Patent Approval - marketscreener.com
Biofrontera extends Ameluz patent to 2043 for acne treatment - Investing.com
Biofrontera Inc. Announces New Patent Protection on Ameluz® until 2043 and the Completion of Patient Enrollment in Phase 2b Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Moderate to Severe Acne Vulgaris - The Manila Times
Biofrontera Inc. announces patent protection on Ameluz until 2043 - TipRanks
Biofrontera Inc. faces Nasdaq delisting over share price By Investing.com - Investing.com Nigeria
Biofrontera Inc. faces Nasdaq delisting over share price - Investing.com Australia
Biofrontera Faces Nasdaq Non-Compliance Notice - TipRanks
Biofrontera (BFRI) to Release Earnings on Thursday - Defense World
Dermatology Leader Biofrontera Announces First Quarter 2025 Earnings Date: Key Details Inside - Stock Titan
Biofrontera Inc. to Report First Quarter FY 2025 Financial Results on May 15, 2025 - ACCESS Newswire
Biofrontera and Almirall Launch the Hats On Challenge to Raise Awareness and Support for Actinic Keratosis - GlobeNewswire
Major Skin Cancer Prevention Campaign Launches as 58M Americans Face Actinic Keratosis Risk - Stock Titan
Biofrontera Inc. Reports Third Quarter and Nine-Month 2024 Financial Results and Provides Business Update - ADVFN
Biofrontera Inc (BFRI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):